Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
KING OF PRUSSIA, Pa., June 21, 2017 -- Aspire Bariatrics, Inc., a commercial-stage medical device company announced today that it received approval to market the AspireAssist®, a novel device for the treatment of obesity, in Australia by the Therapeutic Goods Administration (TGA) and that the first cases using the AspireAssist have been performed in Australia.
“Until the AspireAssist, the only available option to treat obesity in people with severe obesity has been bariatric surgery. Although effective in weight loss, bariatric surgery is not favored by many patients because of its irreversibility and their concern about complications,” said Dr. Patrick Walsh, BSC, MB CHB, FRACP, of Intensiv Weight Loss of Queensland, Australia. “The AspireAssist provides comparable weight loss to bariatric surgery but is reversible, with few and minor complications.”
“We are pleased to be able to offer the AspireAssist as a treatment option for people with obesity in Australia. Australia has been one of the most forward-thinking countries in the treatment of obesity and we look forward to expanding our presence there,” said Katherine Crothall, PhD, President & CEO of Aspire Bariatrics.
About Aspire Bariatrics, Inc.
Aspire Bariatrics is a commercial-stage medical device company with a minimally-invasive, endoscopic device, the AspireAssist®, to treat obesity. In June 2016, the Company received premarket approval (PMA) from the FDA. AspireAssist Therapy is an alternative to bariatric surgery, providing comparable weight loss, but with far better safety, complete reversibility, and at a significantly lower cost than bariatric surgery. The therapy provides a holistic approach to patient development of improved eating behaviors, reflected in significant improvement in quality of life and high satisfaction with the therapy. www.aspirebariatrics.com.
Contact for Investors and Media Kathy Crothall, PhD President and CEO (610) 590-1568 [email protected]
